Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 2 min ago
Peer-reviewedCC BYFrontiers in public health

Rabies immunoglobulin utilization and delayed presentation following category III rabies exposure: a 10-year retrospective study in Hangzhou, China

  • Jing Wang1
  • Weiwei Cai1
  • Jiaxin Chen2
  • Jing Chen3
  • Wanli Yang3
  1. 1Department of Infectious Disease Control and Prevention, Hangzhou Center for Disease Control and Prevention (Hangzhou Health Supervision Institution) , ,
  2. 2Department of Epidemiology and Biostatistics, School of Public Health and The Key Laboratory of Intelligent Preventive Medicine of Zhejiang Province, Zhejiang University School of Medicine , ,
  3. 3Department of General Medicine, Hangzhou Occupational Disease Prevention and Treatment Hospital , ,
Read full textPDFDOICite

Abstract

Background: Rabies is an almost invariably fatal, vaccine-preventable zoonosis. Rabies immunoglobulin (RIG) is recommended for Category III exposures, yet real-world RIG utilization remains poorly characterized. This study examined temporal trends and factors associated with RIG utilization and delayed presentation among Category III exposure patients in China.

Methods: A retrospective study was conducted using clinical records of Category III exposure patients presenting to a high-volume rabies prevention clinic in Hangzhou, China, from 2015 to 2024. Calendar year 2018 was treated as a temporal reference year for descriptive comparison. Multivariable logistic regression identified factors associated with RIG non-administration and delayed presentation (>24 h post-exposure).

Results: A total of 14,270 eligible cases were analyzed. Overall RIG utilization was 37.54%, declining from 53.09% in 2015 to 7.14% in 2022. RIG non-administration was independently associated with male sex (OR 1.20, 95% CI 1.11–1.29), age 18–59 years (OR 3.25, 95% CI 2.95–3.59), exposure at home (OR 1.47, 95% CI 1.33–1.63), presentation in 2018 (OR 2.38, 95% CI 2.01–2.82) and in 2019–2024 (OR 4.49, 95% CI 3.96–5.09), and delayed presentation (OR 1.43, 95% CI 1.32–1.55). The overall delayed presentation rate was 34.47%; independent risk factors included age 18–59 years (OR 1.37, 95% CI 1.24–1.52), exposure at home (OR 1.57, 95% CI 1.41–1.74), and presentation in 2018 (OR 1.61, 95% CI 1.40–1.86) and in 2019–2024 (OR 1.77, 95% CI 1.62–1.94).

Conclusion: RIG utilization was low and showed marked temporal variation during 2015–2024, and one third of patients presented more than 24 h after exposure. Both outcomes were concentrated among working-age adults and domestic exposure settings. These findings describe service utilization patterns and identify subgroups in which gaps in PEP delivery are concentrated; targeted risk communication and routine monitoring of RIG utilization and presentation timeliness are needed.

Related

  1. Higher observed 12-month relapse-free survival with satralizumab than with rituximab in aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder: a multicenter retrospective cohort study
    Xiao Lin, Jicheng Zhang, Lei Chen +16
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0ImmunologyFrontiersCrossref
  2. Optimized Epitope-Flanking Sequences Enhance Antigen Presentation and T-Cell Responses Following mRNA Vaccination.
    Marie-Pierre Hardy, Gabriel Ouellet-Lavallée, Catherine Thériault +9
    CellsPeer-reviewedCC BYFull textImmunologyEurope PMC
  3. Association of epilepsy with utilization and acute outcomes following cardiac surgery
    Konmal Ali, Syed Shaheer Ali, Troy Coaston +2
    PLOS OnePeer-reviewedCC BYFull textGeneral biologyEpidemiology & public healthPLOSEurope PMCPMC
  4. Nutritional status, clinical burden, and healthcare utilization among pediatric outpatients with congenital heart disease: A retrospective cross-sectional study from Indonesia
    Putri Amelia, Lourents Christian Dika Sahertian, Rizky Adriansyah +1
    PLOS OnePeer-reviewedCC BY 4.0Full textDevelopmental biologyCardiovascular medicinePLOS
  5. Visual outcomes and headache in intracranial hypertension following cerebral venous sinus thrombosis: A retrospective cohort study
    Theresia Knoche, Ivo Grueninger, Charlotte Pietrock +2
    PLOS OnePeer-reviewedCC BY 4.0NeuroscienceCardiovascular medicinePLOS

Cite

BibTeXRIS
BibTeX
@article{wang2026rabies,
  title = {{Rabies immunoglobulin utilization and delayed presentation following category III rabies exposure: a 10-year retrospective study in Hangzhou, China}},
  author = {Jing Wang and Weiwei Cai and Jiaxin Chen and Jing Chen and Wanli Yang},
  journal = {Frontiers in public health},
  year = {2026},
  month = oct,
  doi = {10.3389/fpubh.2026.1916685},
  url = {https://europepmc.org/article/PMC/PMC13690772},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Rabies immunoglobulin utilization and delayed presentation following category III rabies exposure: a 10-year retrospective study in Hangzhou, China
AU  - Jing Wang
AU  - Weiwei Cai
AU  - Jiaxin Chen
AU  - Jing Chen
AU  - Wanli Yang
PY  - 2026
DA  - 2026/10/09
JO  - Frontiers in public health
DO  - 10.3389/fpubh.2026.1916685
UR  - https://europepmc.org/article/PMC/PMC13690772
AB  - Background: Rabies is an almost invariably fatal, vaccine-preventable zoonosis. Rabies immunoglobulin (RIG) is recommended for Category III exposures, yet real-world RIG utilization remains poorly characterized. This study examined temporal trends and factors associated with RIG utilization and delayed presentation among Category III exposure patients in China.  Methods: A retrospective study was conducted using clinical records of Category III exposure patients presenting to a high-volume rabies prevention clinic in Hangzhou, China, from 2015 to 2024. Calendar year 2018 was treated as a temporal reference year for descriptive comparison. Multivariable logistic regression identified factors associated with RIG non-administration and delayed presentation (>24 h post-exposure).  Results: A total of 14,270 eligible cases were analyzed. Overall RIG utilization was 37.54%, declining from 53.09% in 2015 to 7.14% in 2022. RIG non-administration was independently associated with male sex (OR 1.20, 95% CI 1.11–1.29), age 18–59 years (OR 3.25, 95% CI 2.95–3.59), exposure at home (OR 1.47, 95% CI 1.33–1.63), presentation in 2018 (OR 2.38, 95% CI 2.01–2.82) and in 2019–2024 (OR 4.49, 95% CI 3.96–5.09), and delayed presentation (OR 1.43, 95% CI 1.32–1.55). The overall delayed presentation rate was 34.47%; independent risk factors included age 18–59 years (OR 1.37, 95% CI 1.24–1.52), exposure at home (OR 1.57, 95% CI 1.41–1.74), and presentation in 2018 (OR 1.61, 95% CI 1.40–1.86) and in 2019–2024 (OR 1.77, 95% CI 1.62–1.94).  Conclusion: RIG utilization was low and showed marked temporal variation during 2015–2024, and one third of patients presented more than 24 h after exposure. Both outcomes were concentrated among working-age adults and domestic exposure settings. These findings describe service utilization patterns and identify subgroups in which gaps in PEP delivery are concentrated; targeted risk communication and routine monitoring of RIG utilization and presentation timeliness are needed.
SN  - 2296-2565
ER  -